1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer

Earlier Data Showed Better Results For Roche Pairing

 
• By Joseph Haas

While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.

Lung Cancer
Updated data put Cabometyx's utility in lung cancer in doubt

Exelixis, Inc. will present updated results from a combination trial it is conducting with Roche Holding AG in solid tumors at the American Society for Clinical Oncology annual meeting, being held 3-7 June, and also will outline data from a small investigator-initiated study of its tyrosine kinase inhibitor (TKI) Cabometyx with Merck & Co., Inc.’s Keytruda in recurrent metastatic head-and-neck squamous cell carcinoma (RMHNSCC).

COSMIC-021, a 914-patient, Phase Ib basket study, is testing Cabometyx (cabozantinib) monotherapy as well as combination therapy with Roche’s anti-PD-L1...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.